# US 2013/0156725 A1 · Random pentapolymer for treatment of autoimmune diseases > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2013/0156725 A1 - Document ID: US20130156725A1 - Status: Published application - Kind: A1 - Application number: 13/764,460 - Filed: 2013-02-11 - Published: 2013-06-20 - Earliest claimed: 2011-04-21 - Assignees: Mapi Pharma Ltd. - Inventors: Ehud MAROM; Shai RUBNOV - Web page: https://patentgrep.com/patent/US20130156725A1 ## CPC - C08G 69/10: Alpha-amino-carboxylic acids {(polysuccinimides C08G73/1092)} - A61K 31/785: Polymers containing nitrogen - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia - C07K 14/001: {by chemical synthesis} - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - C08G: MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) ## Abstract The present invention relates to a synthetic polypeptide which is a random linear pentapolymer comprising alanine, glutamic acid, lysine, tyrosine and phenylalanine and use thereof in treating autoimmune diseases, in particular multiple sclerosis. ## Claims ### Claim at position 1 1-26. (canceled) ### Claim 27 A pentapolymer or a salt thereof, which is a linear random copolymer of alanine, glutamic acid, lysine, tyrosine and phenylalanine. ### Claim 28 (depends on 27) The pentapolymer according to claim 27, containing from about 15 to about 120 amino acids. ### Claim 29 (depends on 28) The pentapolymer according to claim 28, having an average molecular weight of about 2,000 to about 20,000 Da. ### Claim 30 (depends on 29) The pentapolymer according to claim 29, having an average molecular weight of about 5,000 to about 15,000 Da. ### Claim 31 (depends on 27) The pentapolymer according to claim 27, comprising L amino acids, D-amino acids or a mixture of L- and D-amino acids. ### Claim 32 (depends on 27) The pentapolymer according to claim 27, wherein the amino acids are in molar ratio of: from about 2.0 to about 3.2 alanine; from about 1.4 to about 2.0 glutamic acid; from about 4.4 to about 4.6 lysine; from about 0.9 to about 1.1 tyrosine; and from about 0.8 to about 1.2 phenylalanine. ### Claim 33 (depends on 27) The pentapolymer according to claim 27, wherein the molar ratio of alanine to glutamic acid to lysine to tyrosine to phenylalanine is about 2.5:1.9:4.5:1.0:0.9, respectively. ### Claim 34 (depends on 27) A pharmaceutical composition comprising a therapeutically effective amount of the pentapolymer according to claim 27 and a pharmaceutically acceptable carrier. ### Claim 35 (depends on 34) The pharmaceutical composition according to claim 34, suitable for parenteral administration by subcutaneous (SC), intravenous (IV), intramuscular (IM), intradermal (ID), or intraperitoneal (IP) injection. ### Claim 36 (depends on 27) A long acting pharmaceutical composition comprising a therapeutically effective amount of the pentapolymer according to claim 27 in a depot form suitable for administration at a medically acceptable location in a subject in need thereof. ### Claim 37 (depends on 36) The long acting pharmaceutical composition according to claim 36, further comprising a pharmaceutically acceptable biodegradable or non-biodegradable carrier selected from PLGA, PLA, PGA, polycaprolactone, polyhydroxybutyrate, polyorthoesters, polyalkaneanhydrides, gelatin, collagen, oxidized cellulose, and polyphosphazene. ### Claim 38 (depends on 27) A method of treating an autoimmune disease comprising administering to a subject in need thereof an effective amount of the pentapolymer according to claim 27. ### Claim 39 (depends on 38) The method according to claim 38, wherein the autoimmune disease is multiple sclerosis. ### Claim 40 (depends on 39) The method according to claim 39, wherein the pentapolymer is administered to reduce the frequency of relapses in patients with Relapsing-Remitting Multiple Sclerosis (RRMS). ### Claim 41 (depends on 38) The method according to claim 38, wherein the pentapolymer is incorporated into a long lasting composition in a depot form suitable for administration at a medically acceptable location in the subject. ### Claim 42 (depends on 38) The method according to claim 38, comprising administering the pentapolymer in combination with at least one additional active agent.